Alterity Therapeutics to Present at Major Biotech Event
Alterity Therapeutics, a biotechnology enterprise focused on crafting disease-modifying treatments for neurodegenerative conditions, has revealed that Dr. David Stamler, the CEO, will provide vital updates during the upcoming Biotech Showcase hosted by Peak Asset Management and Monsoon Communications. This event represents a platform for showcasing innovative approaches within the biotech field.
Details of the Presentation
The anticipated presentation is scheduled to take place during the first week of September, spanning local and continental time zones, enabling accessibility for a diverse audience of investors and stakeholders interested in the latest advancements in biotechnology.
Webcast Information for Participants
Participants from Australia can tune in on the specified date and time, while those in the United States will have their corresponding slots. Such coordination aims to ensure a seamless and inclusive engagement with audiences from different regions.
Focus on Neurodegenerative Disease Treatments
Alterity Therapeutics is committed to transforming treatment landscapes for individuals impacted by neurodegenerative diseases. Their primary focus is on creating effective therapies for conditions including Parkinson's disease and related disorders.
Clinical Developments: ATH434
The company has made significant strides with its lead asset, ATH434. It has shown promising clinical results in a Phase 2 trial for Multiple System Atrophy (MSA), a rare and aggressive form of Parkinsonism. These results suggest that ATH434 could become a critical component in addressing the unmet needs within this patient population.
Broader Drug Discovery Portfolio
Beyond ATH434, Alterity is propelled by a robust drug discovery platform, working to identify and develop novel chemical compounds aiming to tackle the underlying causes of neurological diseases. This breadth of research highlights Alterity’s comprehensive commitment to advancing the field of medical science.
Company Background
The company operates with bases in both Melbourne, Australia, and San Francisco, California, showcasing its international approach to tackling some of the world’s most challenging health issues. Their work isn’t just about creating medication; it's about enhancing the quality of life for those living with challenging diagnoses.
Engagement with the Community
Alterity is not only an innovator in the lab but also places high importance on community engagement. Their strategy includes communicating openly with stakeholders through presentations and webinars, ensuring transparency and involvement from the investor community.
Contact Information for Interested Parties
For those wishing to connect with the team at Alterity, the company provides dedicated contacts both in Australia and the U.S. Their communication lines are open for queries regarding investments, collaborations, or further insights on ongoing projects.
Australia Contacts
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S. Contacts
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Frequently Asked Questions
What is the role of Alterity Therapeutics?
Alterity Therapeutics focuses on developing therapies for neurodegenerative diseases, particularly looking to create disease-modifying treatments.
What are the key assets being developed by Alterity?
The key asset is ATH434, aimed at treating Multiple System Atrophy, with promising results seen in clinical trials.
When is the presentation scheduled to take place?
The presentation is set for early September, coinciding with the Biotech Showcase event.
How can one participate in the webcast?
Interested parties can register for the Zoom webcast, which will be announced closer to the event.
Who can be contacted for further inquiries regarding investment?
Investment inquiries can be directed to Ana Luiza Harrop for Australia or Remy Bernarda for the U.S.
